Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
10
2021
accepted:
15
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Hepatitis C virus (HCV) is a common cause of progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma worldwide. Despite the availability of effective direct-acting antivirals, patients often have significant hepatic fibrosis at the time of diagnosis due to delay in diagnosis and comorbidities which promote fibrogenesis. Thus, antifibrotic agents represent an attractive adjunctive therapy. Fuzheng Huayu (FZHY), a traditional Chinese medicine botanical formulation, has been used as an antifibrotic agent in chronic HBV infection. Our aim was to assess FZHY in patients with HCV infection and active viremia. We randomized 118 patients with active viremia from 8 liver centers in the U.S. to receive oral FZHY ( FZHY was well tolerated and safe. Patients with baseline Ishak fibrosis stages F3 and F4 had better response rates to FZHY than patients with baseline F0-F2 ( FZHY produced antifibrotic effects in patients with baseline Ishak F3 and F4 fibrosis stages. Reduction in fibrosis severity was zonal and correlated with the severity of inflammation. Based on its tolerability, safety, and efficacy, FZHY should be further investigated as a therapy in chronic liver diseases because of its dual anti-inflammatory and antiibrotic properties.
Sections du résumé
Background
UNASSIGNED
Hepatitis C virus (HCV) is a common cause of progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma worldwide. Despite the availability of effective direct-acting antivirals, patients often have significant hepatic fibrosis at the time of diagnosis due to delay in diagnosis and comorbidities which promote fibrogenesis. Thus, antifibrotic agents represent an attractive adjunctive therapy. Fuzheng Huayu (FZHY), a traditional Chinese medicine botanical formulation, has been used as an antifibrotic agent in chronic HBV infection. Our aim was to assess FZHY in patients with HCV infection and active viremia.
Method
UNASSIGNED
We randomized 118 patients with active viremia from 8 liver centers in the U.S. to receive oral FZHY (
Results
UNASSIGNED
FZHY was well tolerated and safe. Patients with baseline Ishak fibrosis stages F3 and F4 had better response rates to FZHY than patients with baseline F0-F2 (
Conclusions
UNASSIGNED
FZHY produced antifibrotic effects in patients with baseline Ishak F3 and F4 fibrosis stages. Reduction in fibrosis severity was zonal and correlated with the severity of inflammation. Based on its tolerability, safety, and efficacy, FZHY should be further investigated as a therapy in chronic liver diseases because of its dual anti-inflammatory and antiibrotic properties.
Identifiants
pubmed: 35873630
doi: 10.1155/2022/4494099
pmc: PMC9307334
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4494099Informations de copyright
Copyright © 2022 Tarek Hassanein et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
PLoS One. 2015 Dec 31;10(12):e0145953
pubmed: 26720298
Hepatology. 2020 Jun;71(6):1953-1966
pubmed: 31600834
JAMA Netw Open. 2019 Oct 2;2(10):e1912565
pubmed: 31584681
N Engl J Med. 2001 Jul 5;345(1):41-52
pubmed: 11439948
Hepatology. 2013 Jun;57(6):2164-70
pubmed: 23280550
Zhonghua Gan Zang Bing Za Zhi. 2014 Aug;22(8):594-9
pubmed: 25243960
J Viral Hepat. 2013 Sep;20(9):600-1
pubmed: 23910643
J Viral Hepat. 2014 May;21 Suppl 1:60-89
pubmed: 24713006
Hepatology. 1989 Jul;10(1):72-6
pubmed: 2472341
J Ethnopharmacol. 2009 Jul 6;124(1):142-50
pubmed: 19501992
Arch Clin Biomed Res. 2020;4(5):561-580
pubmed: 33210080
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
Liver. 1988 Dec;8(6):325-9
pubmed: 2464118
J Hepatol. 2020 Apr;72(4):613-626
pubmed: 31697972
Evid Based Complement Alternat Med. 2020 Nov 25;2020:8591892
pubmed: 33293994
J Hepatol. 2014 Aug;61(2):260-269
pubmed: 24583249
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
World J Gastroenterol. 2005 May 21;11(19):2892-9
pubmed: 15902724
Zhonghua Gan Zang Bing Za Zhi. 2013 Sep;21(9):668-73
pubmed: 24160341
Lancet. 2019 Nov 30;394(10213):2012-2024
pubmed: 31727409
Zhonghua Gan Zang Bing Za Zhi. 2015 Apr;23(4):295-6
pubmed: 26427080
Hepatology. 2017 Jun;65(6):1891-1903
pubmed: 28133774
Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):221-6
pubmed: 22475144
J Viral Hepat. 2017 Oct;24 Suppl 2:4-7
pubmed: 29105284
Beitr Pathol. 1976 May;157(3):215-43
pubmed: 1275864
PLoS One. 2018 Jun 20;13(6):e0199166
pubmed: 29924825
Liver Int. 2015 Jan;35 Suppl 1:71-7
pubmed: 25529090
Sci Rep. 2016 Jan 06;6:18841
pubmed: 26733102
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
BMC Complement Altern Med. 2014 Nov 18;14:449
pubmed: 25407538
Gut. 2020 Jun;69(6):1116-1126
pubmed: 31563875
Neural Comput. 1999 Aug 15;11(6):1427-53
pubmed: 10423502